Risk of inflammatory reactions in patients with coexisting infections following HMGB1 administration
First written in FY2019. 2 of 3 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「These facts indicate a risk that intravenous administration of HMGB1 protein as a pharmaceutical could trigger a strong local or systemic inflammatory response in patients with severe concomitant infections.」
The risk of an inflammatory response associated with administering HMGB1 to patients with severe infections has been reaffirmed. - FY2024RestatedAnnual report
「These facts indicate a risk that intravenous administration of HMGB1 protein as a pharmaceutical could trigger a strong local or systemic inflammatory response in patients with severe concomitant infections.」
The risk of an inflammatory response associated with administering HMGB1 to patients with severe infections has been reaffirmed. - FY2019First statedAnnual report
「These facts indicate a risk that intravenous administration of HMGB1 protein as a pharmaceutical could trigger a strong local or systemic inflammatory response in patients with severe concomitant infections.」
The Company explains the safety risk associated with administering HMGB1 to patients with severe infections, based on its inflammation-inducing effects.